An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders

Detalhes bibliográficos
Autor(a) principal: Mendonça, Marcelo
Data de Publicação: 2022
Outros Autores: Cotovio, Gonçalo, Barbosa, Raquel, Grunho, Miguel, Oliveira-Maia, Albino J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/142071
Resumo: Funding Information: AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. (2019–2020), is recipient of a grant from Schuhfried GmbH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. (EudraCT number 2017-003288-36 and 2020-001348-25), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. (EudraCT NUMBER: 2019-002992-33). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Publisher Copyright: Copyright © 2022 Mendonça, Cotovio, Barbosa, Grunho and Oliveira-Maia.
id RCAP_cfcb2e0c914bf44be75d6c64b08acfc9
oai_identifier_str oai:run.unl.pt:10362/142071
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling An Argument in Favor of Deep Brain Stimulation for Uncommon Movement DisordersThe Case for N-of-1 Trials in Holmes Tremorconnectivitydeep brain stimulationHolmes tremormovement disordersn-of-1 trialsNeuropsychology and Physiological PsychologyNeurologyPsychiatry and Mental healthBiological PsychiatryBehavioral NeuroscienceSDG 3 - Good Health and Well-beingFunding Information: AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. (2019–2020), is recipient of a grant from Schuhfried GmbH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. (EudraCT number 2017-003288-36 and 2020-001348-25), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. (EudraCT NUMBER: 2019-002992-33). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Publisher Copyright: Copyright © 2022 Mendonça, Cotovio, Barbosa, Grunho and Oliveira-Maia.Deep brain stimulation (DBS) is part of state-of-the-art treatment for medically refractory Parkinson’s disease, essential tremor or primary dystonia. However, there are multiple movement disorders that present after a static brain lesion and that are frequently refractory to medical treatment. Using Holmes tremor (HT) as an example, we discuss the effectiveness of currently available treatments and, performing simulations using a Markov Chain approach, propose that DBS with iterative parameter optimization is expected to be more effective than an approach based on sequential trials of pharmacological agents. Since, in DBS studies for HT, the thalamus is a frequently chosen target, using data from previous studies of lesion connectivity mapping in HT, we compared the connectivity of thalamic and non-thalamic targets with a proxy of the HT network, and found a significantly higher connectivity of thalamic DBS targets in HT. The understanding of brain networks provided by analysis of functional connectivity may thus provide an informed framework for proper surgical targeting of individual patients. Based on these findings, we argue that there is an ethical imperative to at least consider surgical options in patients with uncommon movement disorders, while simultaneously providing consistent information regarding the expected effectiveness and risks, even in a scenario of surgical-risk aversion. An approach based on n-of-1 DBS trials may ultimately significantly improve outcomes while informing on optimal therapeutic targets and parameter settings for HT and other disabling and rare movement disorders.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNMendonça, MarceloCotovio, GonçaloBarbosa, RaquelGrunho, MiguelOliveira-Maia, Albino J.2022-07-18T22:27:11Z2022-06-172022-06-17T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/142071eng1662-5161PURE: 45372233https://doi.org/10.3389/fnhum.2022.921523info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:19:23Zoai:run.unl.pt:10362/142071Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:50:07.251129Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
The Case for N-of-1 Trials in Holmes Tremor
title An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
spellingShingle An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
Mendonça, Marcelo
connectivity
deep brain stimulation
Holmes tremor
movement disorders
n-of-1 trials
Neuropsychology and Physiological Psychology
Neurology
Psychiatry and Mental health
Biological Psychiatry
Behavioral Neuroscience
SDG 3 - Good Health and Well-being
title_short An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
title_full An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
title_fullStr An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
title_full_unstemmed An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
title_sort An Argument in Favor of Deep Brain Stimulation for Uncommon Movement Disorders
author Mendonça, Marcelo
author_facet Mendonça, Marcelo
Cotovio, Gonçalo
Barbosa, Raquel
Grunho, Miguel
Oliveira-Maia, Albino J.
author_role author
author2 Cotovio, Gonçalo
Barbosa, Raquel
Grunho, Miguel
Oliveira-Maia, Albino J.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Mendonça, Marcelo
Cotovio, Gonçalo
Barbosa, Raquel
Grunho, Miguel
Oliveira-Maia, Albino J.
dc.subject.por.fl_str_mv connectivity
deep brain stimulation
Holmes tremor
movement disorders
n-of-1 trials
Neuropsychology and Physiological Psychology
Neurology
Psychiatry and Mental health
Biological Psychiatry
Behavioral Neuroscience
SDG 3 - Good Health and Well-being
topic connectivity
deep brain stimulation
Holmes tremor
movement disorders
n-of-1 trials
Neuropsychology and Physiological Psychology
Neurology
Psychiatry and Mental health
Biological Psychiatry
Behavioral Neuroscience
SDG 3 - Good Health and Well-being
description Funding Information: AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. (2019–2020), is recipient of a grant from Schuhfried GmbH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. (EudraCT number 2017-003288-36 and 2020-001348-25), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. (EudraCT NUMBER: 2019-002992-33). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Funding Information: GC was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/130210/2017). RB was supported by Fundação para a Ciência e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Prémio João Lobo Antunes by Santa Casa da Misericórdia de Lisboa. AJO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/MCTES and co-funded by FEDER, under the Partnership Agreement Lisboa 2020 – Programa Operacional Regional de Lisboa. GC and AJO-M were supported by grant FCT-PTDC/MED-NEU/31331/2017, funded by FCT/MCTES. MM and AJOM were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease. MM was supported by grant UIBD/04443/2020, funded by FCT/MCTES. Publisher Copyright: Copyright © 2022 Mendonça, Cotovio, Barbosa, Grunho and Oliveira-Maia.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-18T22:27:11Z
2022-06-17
2022-06-17T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/142071
url http://hdl.handle.net/10362/142071
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1662-5161
PURE: 45372233
https://doi.org/10.3389/fnhum.2022.921523
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138098710315008